Context Therapeutics (NASDAQ:CNTX) CEO Marty Lehr joins Natalie Stoberman from the Proactive studio to discuss its lead T cell-engaging bispecific antibody clinical development candidate to target Claudin 6 (CLDN6) positive cancers.
Lehr says CTIM-76 is a CLDN6 x CD3 bispecific antibody that shows high selectivity for ovarian, endometrial, testicular, and gastric cancers. Lehr adds that the antibody's specificity suggests its potential to address the need for potent therapeutic modalities for cancer without compromising patient safety.